Remifentanil for the I-gel and Laryngeal Mask Airway Insertion
Information source: Ajou University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Supraglottic Airways for General Anesthesia
Intervention: remifentanil (Drug); i-gel (Device); laryngeal mask airway (Device); propofol (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Ajou University School of Medicine Official(s) and/or principal investigator(s):
Jong Yeop Kim, MD, Study Director, Affiliation: Ajou University School of Medicine
Overall contact:
Jong Yeop Kim, MD, Phone: 82-31-219-5574, Email: kjyeop@ajou.ac.kr
Summary
Structural differences of supraglottic airway devices could influence the different
compressive forces in the oropharyngeal cavities, and require different depth of anesthesia.
The addition of remifentanil during propofol anesthesia facilitates the insertion of
laryngeal mask airway (LMA) with minimal adverse hemodynamic disturbances. This study was
designed to determine the effect-site concentration of remifentanil in 50% of patients
(EC50) and 95% of patients (EC95) for successful i- gel insertion, and compare those for LMA
insertion during propofol target-controlled infusion (TCI).
Clinical Details
Official title: Comparison of the Effect-site Concentration of Remifentanil for Insertion of the I-gel and Laryngeal Mask Airway During Propofol Anesthesia
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: successful insertion of i-gel and LMA
Detailed description:
Anesthesia was induced with propofol TCI at the effect-site concentration of 5 μg/ml, and
the predetermined effect-site concentration of remifentanil was started simultaneously. The
remifentanil concentration was determined using modified Dixon's up-and-down method (initial
concentration: 3. 0 ng/ml, step size: 0. 5 ng/ml). Five minutes later, i- gel or LMA insertion
was attempted. The response of the patients to the insertion of LMA was classified as either
'movement' or 'no movement'.
Eligibility
Minimum age: 19 Years.
Maximum age: 60 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- ASA I-II patients undergoing general anesthesia for short elective surgery (<2 hr)
Exclusion Criteria:
- G-E reflux
- obesity (BMI>30)
- anticipated difficult airway
Locations and Contacts
Jong Yeop Kim, MD, Phone: 82-31-219-5574, Email: kjyeop@ajou.ac.kr
Ajou University hospital, Suwon 443-721, Korea, Republic of; Recruiting
Jong Yeop Kim, MD, Email: kjyeop@ajou.ac.kr
Additional Information
Starting date: March 2015
Last updated: March 5, 2015
|
